This article deals primarily with the selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and evaluated, and those that warrant future investigations. Various scientific and practical issues related to the production and availability of these radionuclides is briefly addressed. At brookhaven national laboratory (BNL), we have developed a paradigm that involves specific individual 'dual-purpose' radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy, and which when molecularly (selectively) targeted using appropriate carriers, would allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may thus potentially bring us closer to the age-long dream of personalized medicine for performing tailored low-dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pretherapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc., followed by performing higher-dose targeted molecular therapy in the same patient with the same radiopharmaceutical. As an example, our preclinical and clinical studies with the theragnostic radionuclide Sn-117m are covered in somewhat greater detail.
INTRODUCTION
Nuclear medicine has experienced an exponential resurgence of interest in radiotherapeutic procedures. Using unsealed sources for radionuclide therapy is not a new concept; it has been around for over 5 decades starting with
10.5005/jp-journals-10028-1054
the development of among others the treatment of thyroid disorders with radioiodine. However, recent advances in molecular biology have led to a better understanding of cancer and other disease states, and parallel research has shown promise for biological vehicles, such as monoclonal antibodies, specific proteins and peptides, and a variety of other intelligently designed molecules, to serve as specific carriers to deliver cell killing radiation into tumors in a highly localized fashion. These developments have led to a renewed interest in the exciting possibility of treating human malignancies with the systemic administration of radionuclides. A number of other relatively new modalities, such as the treatment of metastatic bone pain, radiation synovectomy, bone marrow ablation, and others, have given additional impetus to need for research on therapeutic radionuclides tailored for specific applications.
A major advantage of radionuclides is that they emit radiation of different radiobiological effectiveness and range of action. This offers the possibility of choosing a nuclide the physical and nuclear characteristics of which are matched with a particular tumor type, or the disease under treatment. In addition, certain dual-purpose ('theragnostic') radionuclides that seem to offer the exciting potential of pretherapy low dose imaging followed by higher dose treatment in the same patient, thus possibly bringing us a major step closer to personalized medicine, are discussed in somewhat greater detail in this article. We are reintroducing and reinforcing this relatively novel paradigm that involves specific individual theragnostic radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy, and which when molecularly (selectively) targeted using appropriate carriers, would allow pretherapy low dose imaging plus higher dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may thus potentially bring us a major step closer to the age-long dream of personalized medicine for performing tailored low dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pretherapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc. followed by performing higher dose targeted molecular therapy in the same patient with the same radiopharmaceutical. Beginning in the 1980's, our work at
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Brookhaven National Laboratory (BNL) with such a 'dualpurpose' radionuclide, tin-117m, convinced us that it is arguably one of the most promising theragnostic radionuclides and we have continued to concentrate on this effort. Our results with this radionuclide are therefore covered in somewhat greater detail in this paper.
THERAGNOSTIC RADIONUCLIDES
As mentioned above, certain radionuclides or radionuclide pairs have emissions that allow pretherapy information with low dose imaging, followed by higher dose therapy in the same patient. [1] [2] [3] [4] Such dual-purpose theragnostic radionuclides, for example I-131, or the pair I-124/I-131 have been around and used for imaging followed by therapy, without consideration to the fact that the optimum radionuclide or the optimum radionuclide pair were not scientifically or methodically chosen with this requirement and/or with the particular disease in mind. Over 2 decades ago, when Y-90 began to be promoted for radioimmunotherapy and was undergoing rapid development, it was considered necessary to use In-111-monoclonal antibody (mAb) as a surrogate to carry out biodistribution and imaging studies in order to predict the dosimetry and toxicity prior to doing the therapy with Y-90-mAb, because of the lack of imageable photons in Y-90 emissions. After some very careful studies, the Julich group 5 and our own group at Brookhaven 6, 7 showed that at best, it was hazardous to do so because these were two different elements whose biochemistry had many similarities but also many striking dissimilarities as well. Interestingly, this practice still continues, because of the lack of an alternate solution. 8 In such a situation, it would have been best to use the positron emitter Y-86, a congener of Y-90, and therefore with the same chemical and biochemical properties, to carry out pretherapy positron emission tomography (PET) imaging, so that imaging predicts biodistribution and dosimetry in a reliable, individualized fashion, and thus also predicts as to which patients will respond to the radionuclide therapy with Y-90 and which will not. However, Y-86 until very recently has not been available at all or only in insufficient quantities for this purpose. This situation is now changing and in many cases, if the therapeutic isotope has no photon emission, suitable congeners for imaging are becoming more and more available.
It is noteworthy that a number of such radionuclides or radionuclide pairs do exist [1] [2] [3] [4] and it would make a lot of sense to direct their use for the development of 'theragnostic radiopharmaceuticals'. It is important to stress that ideally, for theragnostic use, the molecularly targeted radiopharmaceutical should constitute the same dual-purpose radionuclide with both imaging and therapeutic emissions. In the second best situation, as mentioned above for the Y-90 situation, a radionuclide pair (imaging photon emitter, either gamma or positron, and a congener of the therapeutic particle emitter, with the same electronic structure) can be used as well. One caveat here, which is a fact of life, is that even though many theragnostic PET/therapy radionuclide pairs may have the same electronic structure, their production and processing methodologies may be significantly different leading to the fact that their chemistry and in vivo behavior may be different as well due to differences in chemical species, charge, specific activity, etc. and/or the amount of chemical and radionuclidic and chemical impurities, which cannot be totally removed.
Another caveat that one has to deal with is the issue of halflife of the imaging PET congener which in most cases might be much shorter than the usually (desirable) longer halflife of the therapeutic congener. In most situations, the determination of longer term biodistribution and dosimetry would be crucial but this information would not be achievable using the shorter lived PET congener for pretherapy imaging.
To re-emphasize, the theragnostic radionuclides or radionuclide pairs would initially allow molecular imaging (SPECT/CT or PET/CT) to provide the required and useful pretherapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD). If the imaging results then warrant it, it would be safe and appropriate to follow-up with dose ranging experiments to allow higher dose targeted molecular therapy with the greatest effectiveness. These factors are especially important in order to be able to do tailored imaging plus therapy (personalized medicine) in the same patient with the same radiopharmaceutical. [1] [2] [3] [4] There are indeed a number of individual radionuclides that emit both imaging photons and therapeutic electrons and which would be potentially excellent choices for theragnostic applications (Table 1) . Some of the most promising PET/therapy radionuclide pairs are shown in Table 2 . The lists included in both Tables 1 and 2 are not all-inclusive but consist of selected radionuclides and radionuclide pairs that are or could be made available in sufficient quantities to be of practical value, and which show the required combination of nuclear, physical and chemical properties, and thus the greatest promise. Some other criteria for inclusion were arbitrarily set at a minimum of 20% photon/positron emission for imaging, and a sufficiently abundant therapeutic particle emission consisting of medium ( -) to high linear energy transfer (LET) electrons. the class of alpha and Auger electron emitters, 1-4,9-11 but these have not been included in this theragnostic group of radionuclides (except Ac-225/Bi-213) since their availability is either limited or not enough preclinical and clinical experimental data have thus far been available. As mentioned above, a major problem that remains yet to be completely resolved is the lack of availability of a number of the best candidate therapeutic radionuclides, in particular the theragnostic radionuclides or PET/SPECT radionuclide pairs, in sufficient quantities and/or in a nocarrier-added (NCA) form. Methods have already been studied and developed for the production of research quantities of certain theragnostic radionuclides and radionuclide pairs listed in Tables 1 and 2 
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47 TiO 2 targets were irradiated at HFIR for periods ranging from a few hours to several days. 19 The experimental results are lower than the theoretical ones, perhaps due to differences in the actual neutron spectrum when the irradiations occurred compared to the theoretical neutron spectrum. High production yields using the PTP positions at the HFIR were obtained. These results indicate that Sc-47 can be produced at a reactor using the 47 Ti(n,p) reaction in quantities sufficient for theragnostic applications. For example, at HFIR a 3.35 day (one half-life of Sc-47) irradiation of a 10g target would theoretically producẽ 75 Ci of Sc-47 at EOB. Both the Sc-46/Sc-47 and Sc-48/ Sc-47 impurity ratios are less than 0.4% at EOB (end of bombardment), leading to a product with greater than 99.5% radiopurity. 18, 19 The specific activity of Sc-47 depends essentially on the scandium content of the enriched target material. Scandium is not a ubiquitous contaminant, such as lead or copper, and would not be expected to be introduced during processing of the target. These expectations were borne out when several product samples were analyzed with ICP-AE and no stable Sc was detected. 19 Since scandium was not detected in batches of target material, stable scandium content can be assumed to be the reported detection limit. The specific activities are high enough for antibody labeling applications in radioimmunotherapy. Conservatively assuming that an average of two to three scandium-ligand complexes can be attached to each antibody molecule without loss of immunoreactivity, up to 30 mCi (1.16 GBq) of ORNL produced Sc-47 can be used to label 1 mg of a typical IgG antibody (mol. wt. ~150 kDa) given the measured specific activities. 19 Finally, it is necessary to recycle the expensive enriched target material to defray the target cost over many production runs. A simple procedure was developed that recovers 98.5% of the oxide based on precipitation of titanium at basic pH followed by conversion to the oxide using higher temperature. 19 Titanium may be recovered and easily reused since the only titanium activation product is the short lived Ti-51 (t½ = 5.8 minutes) produced by the 50 Ti(n, ) reaction using thermal neutrons. Other radionuclidic impurities that have been detected in recycled material are Ta-182 (t½ = 114.4 days) and Zn-65 (t½ = 244 days). These isotopes are also produced by (n, ) reactions on minor target impurities of stable Ta and Zn. If required, these impurities could easily be separated from the target material using anion-exchange chromatography before precipitation of the titanium. 19 Relative production yields were also determined using the (p, 2n) reaction on 48 Ti(p, 2 pn) 48 Sc reaction pathways have been eliminated. The
Sc-47/Sc-44m ratio is better at lower irradiation energies (Ep < 100 MeV); however, unfortunately the Sc-47/Sc-46 ratios are worse throughout the energy region measured. Thus, this production method would not be suitable for producing Sc-47 with sufficient purity for therapeutic use.
19
Although Cu-67 has long been considered as one of the ideal therapeutic/theragnostic radionuclides (vide infra), its scaled up production with a sufficiently high specific activity is still an issue that has only partially been resolved and further improvements are difficult if not questionable, at this time. With this in mind, we have proposed Sc-47 as a possible replacement for Cu-67 20 as shown in Table 3 . 
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Copper-67
Copper-67, with a 2.6-day half-life, is the longest lived radioisotope of Cu. 21 It provides medium energy emission of 0.6 MeV max (average, 141 keV), photon emissions (184 keV, 48.7%; 93 keV, 16%; 91 keV, 7%), and facile labeling chemistry. It is a very attractive theragnostic radionuclide. [1] [2] [3] [4] The half-life is suitable for imaging slow in vivo pharmacokinetics with agents, such as mAbs and other carrier molecules, and the beta particle energy is appropriate for therapy. The 185-keV gamma ray (49%) permits imaging of the uptake and biodistribution of the agent both before and during therapy administration. It can also be paired with the positron emitter Cu-64 to perform pretherapy biodistribution determinations and dosimetry by PET. However, as mentioned earlier in this article, the use of Cu-67 has been inhibited by a lack of regular availability of sufficient quantities at a cost that researchers can typically afford, as well as the low specific activity issue. 7, 21 In the past several decades, the most typical source in the United States has been the high energy proton irradiation of natural Zn targets, 21 primarily irradiated at either the BLIP (Brookhaven Linac Isotope Producer) at BNL or at the Isotope Production Facility (IPF) at LANL (Los Alamos National Laboratory). These are both large accelerators operated and funded for physics research only part of each year. Thus, in the past, it has not been possible to provide Cu-67 on a time frame suitable to support clinical trials, with the attendant schedule fluctuations and changing patient status. 22, 23 Additionally, the specific activity was at the low end of what was acceptable for antibody therapy, ranging from about 5 to 10 Ci (185-370 GBq) per mg of Cu at EOB. With the construction of a new target station at the IPF at LANL in 2004, the beam intensity and production have improved, but year-round availability still cannot be assured. Recent studies at BNL have tried to determine the causes of the low specific activity. 24 Exhaustive assays of all the reagents used in processing determined that these contribute only approximately 0. Cu reaction performed radiochemically over the energy range of 30 to 70 MeV showed that the yield of Cu-67 is fairly high. 24 Unfortunately, Zn-68 is rather expensive. Also, recycling the target material is considered difficult because of the unavoidable coproduction of long-lived Zn-65 in the target, unless the proton energy is kept around 70 MeV. To try to resolve these issues, BNL has recently been engaged in further research to develop the production of Cu-67 using high energy proton irradiation of enriched Zn-68 targets, followed by selective chemical separation of the pure product. 24 A number of specific challenges were addressed:
(i) Development of very thick electroplated Zn-68 disks as targets, (ii) development of recovery/reuse technique of this expensive material after radiochemical processing, (iii) development of a target capsule that can be sealed and then opened remotely in a hot cell, (iv) development of a rapid highly selective chemical separation process for Cu-67 and (v) performing irradiations and measurements of product radiopurity, chemical purity and labeling efficiency. This research has allowed the prospect for the production capability for Cu-67, using a high beam-current accelerator or cyclotron, in sufficiently large quantities and with a greater than five times of the previously obtained specific activity, to support clinical trials. 24 
Yttrium-86
The Sr, which is rather expensive, and economy requires its recovery and reuse. 5, 13, 14 Recovered Sr-86 will contain radioactive Sr-85 after first irradiation if the proton energy is more than 14 MeV, which would mean that hot cell target assembly will be required. At BNL, we have designed such a target, both halves of which are aluminum for better conductivity, head screws are large enough for remote manipulator handling and silver-coated stainless steel C-rings are used to provide adequate seals. 14 Such a target design was successfully irradiated in the BLIP without any leakage and can be opened and sealed in a hot cell. Modification to increase active area in beam may increase production levels but will require more enriched Sr-86 to be used. However, if really a low energy of 14 MeV is used, the amount of target material needed is not high. Targets of both natural SrCl 2 and enriched SrCl 2 were irradiated yielding 10-13 mCi/Ah of Y-86, giving an EOB batch yield of ~1,000 mCi in 1 hour, which is quite high. 14 Chemical yields of Y-86 ranged from 82 to 93%, and a further improvement is desirable. For labeling purposes, this chemical purity allowed for a labeling yield of 84%, and this needs to be improved further as well. The level of a major radionuclidic impurity, Y-87m, was a disappointing 34 to 55%. The low energy route on enriched Sr-86, which has previously been used 4, 5 has allowed for better material and is now being pursued at BNL for larger-scale production. At BLIP, our first irradiation gave very low yield because the beam spot was larger than the target area. Also, the lowest tunable beam energy at the BLIP is 65.5 MeV, but the nuclear reaction cross-section peak is at 14.5 MeV. The choice of degraders seems to have resulted in too high a target entrance energy. BLIP is not an ideal facility for this low energy reaction, but we carried out these investigations mainly to produce some material to develop a better and quicker radiochemical processing methodology that was short enough to allow for same-day irradiation and shipment, which has recently been accomplished. 14 
ALPHA, AUGER AND CONVERSION ELECTRON EMITTERS Alpha Emitters
As mentioned earlier, targeted alpha radiation therapy can be a very potent treatment of cancer. 25 Due to comparatively short range of alpha particles in tissue and their high LET nature, radiation damage is mainly confined to targeted cells. The radiation burden to the surrounding healthy tissues is low when compared to beta emitters. By facilitating an efficient delivery of alpha-emitting isotope it is possible to achieve a very effective treatment regimen for the types of cancer where microscopic and small volume tumors are present. The effectiveness of alpha radioimmunotherapy has been confirmed in clinical and preclinical trials. 
Astatine-211
Astatine-211 (t½ = 7.2 hours) decays through two paths, each emitting an alpha particle. The mean alpha energy is a potent 6.8 MeV. It is produced by the 209 Bi(,2n) reaction and typically separated from the target by dry distillation into a chloroform solution. 28, 29 A difficulty in this process is that the cyclotron energy must be carefully controlled to minimize the coproduction of astatine-210. This isotope (t½ = 8.1 hours) decays to Po-210 (t½ = 138 d) which is an alpha particle emitting bone seeker in vivo and could cause considerable hematological toxicity. The half-life of At-211 is relatively long compared to the other alpha emitters thus, allowing time for chemistry of labeling and use for molecular carriers with slower tumor uptake. However, it is more easily catabolized and shed after cell internalization of the labeled antibody/antigen complex than the metallic alpha emitters. 30 The main problem that inhibits clinical trials with this isotope is the relatively low nuclear yield and very limited number of cyclotrons capable of producing astatine-211. This situation may be somewhat improved in the coming years when the ARRONAX cyclotron in Nantes, France, as expected, goes into routine operations in early 2013. The in vivo use of targeted NCA Ac-225, in its own right, has received a great deal of attention as well. 34, 35 Because of its ability to produce 4 alpha-emitting daughters, its overall potency to destroy cells is higher. The isotope has been referred to as an in vivo alpha particle nanogenerator because its power proliferates beyond the size of the atom. 35 In addition, the applications of Ac-225
were further extended to encapsulation in liposomes 36 and metallofullerenes. 37 At the Memorial Sloan-Kettering
Cancer Center, a clinical trial for radioimmunotherapy of acute myeloid leukemia with both Bi-213 and Ac-225 has recently been carried out. 38 As mentioned earlier in the text, Ac-225 has been used for radioimmunotherapy both as a potent alpha emitter attached to an antibody and as a generator for the daughter alpha emitter Bi-213 (t½ = 45.7 minutes). 40 It is widely acknowledged that the anticipated growth in demand for Ac-225 will soon exceed the levels extractable from the available uranium-233. 39 At BNL, our intent is to carry out future investigations in an effort to increase the supply of Ac-225. This would involve using the high energy proton spallation reaction 232 Th(p, 2p6n) 225 Ac on natural Thorium. This method has recently been studied and developed at other places, in particular, at the Institute of Nuclear Research (INR) in Troitsk, Russia, using accelerated protons at energies between 90 and 145 MeV in their 160-MeV proton accelerator. 41 This investigation has pointed out that the yield of Ac-225 increases monotonically with the proton energy. Therefore, the BLIP at BNL (200 MeV) would be capable of producing almost twice as much with an incident energy on the target of 192 MeV, with 110 µA beam intensity. The expected outcome of the BNL effort would be the method for Ac-225 production with quality (radionuclidic and chemical purity) suitable for applications both as a radiotherapeutic agent (Ac-225) and as a generator of Bi-213 (theragnostic use). The proposed work will involve development of an optimized Th-232 target for irradiation, development of the chemical procedure for dissolution and processing of irradiated target to selectively separate Ac-225, and carrying out preliminary labeling studies of conventional targeting molecules with Ac-225/ Bi-213 to demonstrate the efficacy of the final purified radioisotope(s) for the eventual protein/antibody labeling applications. At BNL, the method could potentially yield Curie amounts of Ac-225 in a 10-day irradiation period at the BLIP. The produced Ac-225 can be used for radioimmunotherapy as well as for generation of Bi-213 in a quality suitable for clinical trials. Shorter-lived radioisotopes Ac-228, 226, 224 will be coproduced in quantities comparable with those of Ac-225, but the activities of these isotopes will saturate out during the 10-day irradiation. The radionuclidic purity of the Ac-225 can be improved by allowing a cool-off period for the target. Ten days (one t½ of Ac-225) after EOB, the coproduced Ac radionuclides will comprise 1% of the activity of Ac-225. Among these, Ac-227, because of its 21.77-year half-life, is the only radioimpurity that might be of some concern as far as noninvasive imaging is concerned but, in principle, of less concern for theragnostic use. However, this issue would require further investigation and additional studies.
Small quantities of Ac-225 can also be prepared by the reaction 226 Ra(p, 2n) 225 Ac over an energy range of 13 to 20
MeV. 42 The cross-section for this reaction is calculated to reach a peak of 700 mb at 16 MeV but total yield is limited by the small energy range (and target thickness) where this reaction is favorable. Similarly the photonuclear reaction 226 Ra(, n) 225 Ra (t½ = 14.9 days) followed by beta decay to Ac-225 is feasible but requires an extremely large Ra target (~40g) that represents radiological safety issues and availability concerns.
Thus, Ac-225, when produced by the BNL method, could substantially add to the very limited present supply of this promising alpha emitter. According to experimental and theoretical extrapolations, and assuming certain target dimensions, radiochemical processing losses, and so forth, the projected yields from a 10-day irradiation at the 5 high energy accelerators in the world are estimated (from the studies at INR) to be as follows ( 
Auger and Conversion Electron Emitters
The production of metastable nuclei, such as conversion electron emitter Sn-117m and Auger electron emitter Pt195m via neutron radiative capture reactions is characterized by small neutron cross-sections and, hence, low production rates. Metastable nuclei typically have excitation energies on the order of 100 keV, and large differences in angular momentum from ground states (most metastable nuclei have high angular momentum). An alternative route for producing these types of metastable nuclei is through neutron inelastic scattering where the cross-section of the A Z(n, n') Am Z reaction is, in some cases, substantially higher than the crosssection for the (A-1) Z(n, ) Am Z route. As has been shown for the case of Sn-117m 45 the magnitude of gain in the crosssection may compensate for the relatively lower fast neutron flux from a well-moderated fission spectrum. Note that the excitation energy of metastable nuclei will represent the threshold for inelastic scattering. Large research reactors, such as HFIR at ORNL, and HFBR (now closed down) in the United States, and at the Research Institute of Atomic Reactors (RIAR) in Dimitrovgrad, Russia, with significant epithermal and fast neutron fluxes, have been well suited for these types of reactions. A systematic study of the production of Sn-117m, and Pt-195m in the hydraulic tube facility of the HFIR was reported. 46 In all three cases, the yields from the [n, n'] reactions were higher than those obtained from the [n, ] reactions. The relative gains in the specific activity of the unfiltered (no Cd filter) targets were 1.4, for Pt-195m, and 3.3 for Sn-117m. The excitation energies for Sn-117m and Pt-195m are 314.6 and 259.2 keV respectively. Since, the thresholds for these inelastic scattering reactions are well above the cadmium cutoff, Cd filters did not have any effect on the yield of these reactions. The corresponding crosssections for the inelastic neutron scattering reactions for the production of Sn-117m, and Pt-195m are 222 ± 16, and 287 ± 20 mb respectively. A value of 176 ± 14 mb for the cross-section of Sn-117[n, n']Sn-117m reaction obtained at HFBR was reported earlier. 45 
Conversion Electron Emitter Tin-117m
The most common method for Sn-117m production is based on irradiation of tin with neutrons using the 117 Sn(n,
Sn reaction. 45 However, since this reactor production method is based on the inelastic neutron scattering reaction using enriched Sn-117 as a target, it results in Sn-117m with a low specific activity of about 20 Ci/g. 47 Stannic complexes with Sn-117m of such specific activity, particularly Sn-117m
4+
-DTPA, effectively reduce pain from bone metastases without adverse reactions related to bone marrow, as demonstrated by the results presented in Tables 4  and 5. 48 However, such low specific activity does not allow scaling up the therapeutic doses for treating bone metastases. Also it is not acceptable for radioimmunotherapy and for many other applications. Although it is not possible to achieve a higher than about 22mCi/mg of specific activity in the reactor-produced tin-
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47 NCA tin-117m can be produced by proton irradiation of antimony via nuclear reactions (p, 2p3n) or (p, 2p5n) in an accelerator. 45, 49 NCA Sn-117m can also be produced in an accelerator via a large number of other nuclear reactions. Using the 115m In (, pn) 117m Sn reaction over the energy range of 45 to 20 MeV, a relatively pure product is obtained; however, with very small yields. 50 In addition, the nuclear reaction 116 Cd(, 3n) 117m Sn is also very useful for the production of NCA Sn-117m. The thick target yield over the energy range 47  20 MeV is about 150 Ci/Ah. Unfortunately, the present limiting factor for the scaled up production of Sn-117m via this route is the availability and power of existing alpha accelerators and targetry. 51 Using the BLIP at BNL, we have been producing NCA Sn-117m with the natural antimony (natSb) (p, xn) 117m
Sn reaction over the energy range of 38 to 60 MeV for quite some time. 45 This process, with a cross-section of 5 mb, was found enough to produce therapeutic quantities of Sn-117m with high specific activity. The specific activity when assumed to be wholly dependent on the amount of Sn impurity in the Sb target was calculated to be 30,000 mCi/mg for each part per million of Sn in the target. However, further theoretical cross-section calculations at the INR in Troitsk, Russia (vide infra) have demonstrated that the proton energy range should be much broader, perhaps 40 to 130 MeV. 49 The specific activity of Sn-117m depends mainly on the amount of stable tin, which is also generated during the irradiation of natural Sb, and the specific activity can vary from ~1000 to 3000 mCi/mg at EOB, a range that is quite suitable for radiolabeling molecules that bind to saturable in vivo receptors.
More recently, the larger-scale accelerator production and availability of NCA Sn-117m with high purity and high specific activity, targets based on natural or enriched Sb have been developed in our collaborative research between BNL and INR, along with other institutes, including the Institute for Physics and Power Engineering in Obninsk (IPPE) and Moscow State University (MSU), in the neighboring regions in Russia. 49 Within this collaborative research program with BNL, investigations at INR dealt with the development of antimony as wells as antimony/titanium intermetallic targets suitable for the high energy production of NCA tin-117m. For irradiation with the high-intensity proton beam, targets consisting of Sb-monolith encapsulated into shells made of stainless steel or graphite were developed. 49 The shells were filled with metallic antimony as follows. Powdered metallic antimony was inserted into the shells under inert nitrogen atmosphere, and the filled shell was heated at 645 to 660°C. It was found that at higher temperature liquid antimony reacts with iron and can destroy the stainless steel shell during the target preparation or irradiation. Graphite target shell is more reliable since there is no noticeable reaction between graphite and antimony, and graphite has higher heat conductivity than stainless steel [80-120 W/(m·K) vs 20 W/(m·K) at 300°C], providing effective target cooling. After antimony melting and shrinkage, the shell was again filled with powder of antimony and heated to melt again. The target with metallic shell containing a monolith of 29g metallic antimony (a cylinder 9 mm thick, 30 mm in diameter) was hermetically sealed with a threaded plug. The graphite shell targets (plates 32 × 76 × 5 mm, 3 mm of Sb thick each, 19g Sb each) were hermetically sealed with a cover by means of high temperature radiation resistant glue and electroplated outside with nickel in order to protect graphite from reaction with water radiolysis products during irradiation. 49 The irradiated Sb-targets were chemically processed at the hot cell facility at IPPE in Obninsk. The stainless steel shell was dissolved in concentrated HCl while the graphite shell was opened mechanically. The freed Sb monolith was dissolved in concentrated HCl with gradual addition of small amount concentrated HNO 3 . The major amount of Sb (in the form Sb 5+ ) was removed from the solution (10-11 M HCl) by extraction with dibutyl ether. Final purification of NCA Sn-117m from the rest of Sb, coproduced Te-118, 119m, 121m and In-111, 114m was achieved by chromatography on SiO 2 in 0.5 M sodium citrate (Na 3 Cit) solution. Tin isotopes remained adsorbed on SiO 2 while Sb and radioisotopes of Te and In were washed out. Then the column was washed with 0.5 M Na 3 Cit solution and water acidified by citric acid. Finally, tin was eluted from the column with 6 M HCl. Radionuclidic purity of the final solution and the specific activity of Sn-117m in the final product were determined using appropriate counting procedures (spectral emission analysis), and through inductively coupled plasma (ICP) spectrometry. Among other isotopes of tin coproduced with Sn-117m, Sn-113 is the most important impurity. It has a long half-life (115 d), relatively high energy -rays (392 keV) and cannot be chemically separated from Sn-117m. But it is possible to reduce Sn-113 impurity up to almost 1% by lowering the initial proton energy. The optimum range of between 55 and 20 MeV has been demonstrated to be most effective, although at the expense of somewhat reduced Sn-117m product.
52
THERAGNOSTIC STUDIES WITH Sn-117m
Sn-117m (t½ = 14.0 days;  159 keV, 86%) shows considerable promise as a theragnostic radionuclide due to its nuclear, physical and chemical characteristics. As mentioned earlier in this paper, it is certainly one of the best radionuclides for the development of theragnostic radiopharmaceuticals, in particular, for nuclear oncology. In contrast to most other therapeutic beta emitters, Sn-117m decays via isomeric transition, with the emission of three major mono energetic conversion electrons (127, 129 and 152 keV; abundance, 65, 12 and 26% respectively). These emissions with a very high LET have short discrete penetration ranges of between 0.22 (127 keV) and 0.29 mm (152 keV) in water. Therefore, Sn-117m when selectively targeted should be effective for therapy of metastatic disease and for certain other inflammatory conditions (e.g. atherosclerotic disease), causing much reduced myelosuppression and greatly reduced dose to normal organs. 53 This is schematically represented in Figure 1 as well as in Figure 2 54 which shows whole-body autoradiographies performed in mice and rats after the administration of Sn117m(4 + )-diethylenetriamine pentaacetic acid (DTPA), and the highly selective targeting and high uptake in bone by this agent, but not in bone marrow or other organs, suggesting the expected effectiveness of high-LET low energy conversion electrons to produce intense radiation dose within a very short distance without affecting normal tissues, in particular, the radiation-sensitive bone marrow.
53 Figure 3 shows whole body images in a prostate cancer patient, who had developed extensive bone metastases. Scan on the left was obtained using the standard Tc-99m MDP (methylene diphosphonate) imaging agent and the one on the right consists of scans obtained using tin-117m (4  + ) DTPA, an agent which as mentioned above has shown great promise for treatment of metastatic pain in prostate and Figures 4A and B . The uptake of Sn-117m DTPA is both diffuse (T8) and heterogeneous (L1). Partial involvement within a single vertebra indicates nonuniform distribution of radioactivity within the lesion, suggesting heterogeneous distribution of metastatic foci. 55 Thus, the unique therapeutic emissions of Sn-117m also imply that their therapeutic effectiveness will be highly localized and should be lesionspecific and thus more effective. The use of Sn-117m DTPA is also very worth considering for an early-stage disease at which time, there would be the possibility of slowing or even stopping the progression of further metastatic lesions. Moreover, having the 159-keV  photon (86%), which is very similar to that of technetium-99m, Sn-117m is perfect for pretherapy imaging for dosimetry and for other information in the same patient as well as for monitoring the results of treatment. 55 All clinical studies thus, far for bone pain palliation using Sn-117m DTPA were carried out using reactor-produced Sn-117m, with a specific activity ranging between 8 and 20 Ci/g of Sn. More recently, several 50-to 150-mCi samples of NCA Sn-117m produced at INR as well as at the University of Washington alpha cyclotron, have successfully been used and evaluated at BNL, and in collaboration with the Saint Joseph's Translational Research Institute in Atlanta and at other institutions, for effectiveness for theragnostic applications in animal models. 56, 57 Tin-117m, in addition to being a good therapeutic agent for cancer, also shows promise for the noninvasive molecular imaging and treatment of active atheromatous disease [vulnerable plaque (VP), also known as thin-cap fibroatheroma (TCFA)], in the coronary arteries and other areas of vasculature through the use of (i) coronary stents electroplated with Sn-117m or (ii) specific Sn-117m-labeled molecules systemically targeted to VP components.
In the United States, there are, on an average, about 875,000 to 1,000,000 new heart attacks every year, and these are caused by two different types of atherosclerotic disease: Luminal calcified plaque and extraluminal active atheromatous disease leading to the formation of VP (Fig. 6) . Vulnerable (unstable) plaque forms below the lumen in coronary artery walls, and inflammation is the main driver. VP is usually covered by a thin cap on the lumen side. When ruptured, the thin cap 'releases' highly thrombogenic material activating clotting cascade and inducing thrombosis. Approximately more than 120 substances are expressed in ruptured VP (including breast cancer patients. 48 These two scans are almost identical, demonstrating the specificity of tin-117m DTPA localization in bone and in much higher concentration in bone metastases, in fact quantitatively even much better than the Tc-99m MDP. Figures 4A and B , 55 which are from an actual sample of bone tissue from a prostate cancer patient, who was treated with Sn-117m DTPA for bone pain palliation and who donated his body for research after death corroborates the same result as in Figures 2 and 3 . This latter patient had died of his primary cancer 47 days after collagen) and this rupture then results in thrombosis, which can cause unstable angina, chest pain, acute MI, sudden coronary death and stroke. The luminal calcified plaques are easily detected by existing diagnostics, and the patient has a number of treatment options. However, VP develops and models positively outside the arterial lumen (Fig. 6 ) and cannot be detected by noninvasive imaging techniques. Unfortunately, a majority of all significant cardiac events (~70%) leading to MI, including sudden death, are caused by the rupture of these thin-cap fibroatheroma lesions, not lumen atherosclerosis. The properties of Sn-117m as applied to vulnerable plaques are unique and significant.
At therapeutic doses, the conversion electrons from Sn-117m have been shown to reduce inflammation and, thus, are ideal for treating VP's as their range in tissue (~300 m) is approximately the same as the VP thickness in human coronary arteries. Sn-117m-labeled Annexin effectively targets and binds to macrophage cells undergoing apoptosis, which are present in abundance in VP's. In relatively low doses, this agent can image the plaque using traditional SPECT gamma cameras with technetium99m collimators and imaging protocols. Because of the longer half-life of Sn-117m combined with pretargeting techniques, gamma cameras can acquire images long after the nonspecifically bound tin-Annexin has cleared the blood pool thus improving the image quality. 
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Apo-E mouse VP model, in doses that appear to be imaging doses, tin-117m-Annexin has demonstrated a significant anti-inflammatory therapeutic effect. The plaque composition showed significantly less expression of macrophages in the low, middle and high dose treatment groups as compared to the control group. In contrast, smooth muscle cell expression was greater in the middle and high dose groups as compared to the control, and in the low dose group, the difference was statistically significant between the low vs middle and high dose groups. 59 Because inflammatory cells are more radiosensitive than other arterial wall cell types, the conversion electrons should exhibit a beneficial anti-inflammatory effect in diseased coronary arteries. Since 28 days, corresponding to two halflives of Sn-117m, is believed to be roughly the optimum period for neoproliferative tissue suppression, including neointimal proliferation after angioplasty and other primary interventional treatments in the coronary arteries and other vasculature, radiotherapy with Sn-117m should provide highly effective treatment, with minimal collateral damage to adjacent, quiescent arterial wall cells because of its low energy conversion electron emission and short penetration in tissue. Furthermore, such limited energy delivery from a radioactive stent implant may circumvent the problem of cellular overgrowth at the implant edges, known as the 'candy wrapper' effect, which has been observed with previous forms of radioactive stents.
At BNL, a novel radioactive stent stably electroplated with Sn-117m was developed as a therapeutic tool for the treatment of atherosclerotic coronary arteries. 60 Effects on vessel wall inflammation from various doses of electroplated Sn-117m were studied in hyperlipidemic rabbits. Three days after stent implantation in the abdominal aorta [4 doses: 0-(cold tin), 30-, 60-and 150-Ci Sn-117m per 15-mm stent], the rabbits were sacrificed. Immunohistochemical analysis of proliferating macrophages and smooth muscle cells demonstrated that inflammatory cells in the Sn-117m-stented segments were dramatically reduced in a dosedependent manner. 56, 57 The anti-inflammatory therapeutic effectiveness of the tin-117m-stent implants was further demonstrated in a preliminary study in pigs (24 pigs, 72 bare metal stent implants: 0-to 400-Ci Sn-117m per 15-mm stent), which was carried out to investigate the effects on in-stent neointima formation. The electroplating process appeared benign because the response from 'cold' tin-plated stents was indistinguishable from what was observed for routinely used bare metal, 316L surgical stainless steel stents. A profound and unique radiation effect was consistently observed in the higher dose implants, which consisted of a discrete zone of dense connective tissue consolidation in the tunica adventitia, of ~0.25 to 0.30 mm thickness, corresponding to the anticipated tissue penetration of the Sn-117m conversion electron energy. Focal suppression of in-stent neointima formation was also observed, but further study will be needed to determine, with certainty, the therapeutic potential of Sn-117m-electroplated stents for prevention of in-stent restenosis. 61 To summarize, tin-117m shows great promise as a means to reduce inflammatory events following stent implantation, and when delivered systemically to atherosclerotic tissue using specific targeting molecules (e.g. Annexin-V), is effective in low doses to image and in higher doses to reduce the vulnerability for rupturing of unstable coronary artery plaques. NCA Sn-117m is also being developed and tested for the therapy of bone metastases and for use in radioimmunotherapy. A phase I clinical trial for the imaging and treatment of bone metastases using Sn-117m DTPA in prostate cancer patients is in the planning stage for 2013.
CONCLUSION
There are a number of existing and potential future radionuclides for use as unsealed sources for targeted therapy of cancer and for other therapeutic applications in nuclear medicine. The various important therapeutic applications where radionuclide therapy would have an important role to play in, and the radionuclides best suited for that particular type of application, are summarized in Table 6 . It should be noted that this listing is not meant to be exhaustive and additional radionuclides can be added based on present and future work as well as various other considerations. The substantial progress of investigations in areas, such as the treatment of cancer as well as of other inflammatory conditions, such as in bone pain palliation, radiosynovectomy, and of many other disorders that respond to radionuclide therapy, offers renewed hope and promise for the widespread use of internally administered radionuclides for a number of novel and effective therapeutic approaches.
Therapeutic nuclear medicine finally seems to be destined to find its rightful place in the 'personalized' therapy of patients with the use of a number of dual-purpose ('theragnostic') radionuclides or radionuclide pairs that are discussed and emphasized in this article. This paradigm, when properly enforced would constitute a major step forward to meet the challenges of enabling personalized medicine. Implementation of this regimen potentially creates a situation where treatments are better targeted, health systems save money by identifying therapies not likely to be effective for particular patients, and researchers have a better understanding of comparative effectiveness.
Theragnostic radiopharmaceuticals have the power to drive advances in personalized medicine that will offer better-targeted diagnosis and treatments. Using this approach, it would be possible to envision a future where treatments are tailored to individual patients' specific disease parameters and where imaging data could be analyzed in real-time and in advance to predict likely effectiveness of therapy and learn what would or would not work. Oncology is just the beginning; in principle, we should be able to start scientific enquiries to apply this paradigm to other complex disease states, so that the potential for theragnostic radiopharmaceutical biomarkers as a bridge to help us better detect, understand, and treat diseases like CAD, diabetes, and Alzheimer's becomes a reality. However, an increased and continuously reliable availability at reasonable cost of some of the best theragnostic radionuclides has remained a major issue, which must be addressed before we can successfully put this paradigm into routine clinical practice. This issue has been discussed in this paper in some detail, and the evolving new methodologies for the production of a few of the very promising theragnostic radionuclides have been covered.
It is worth emphasizing that our nuclear medicine modality is the only modality that can fulfill the dream of carrying out tailored personalized medicine by way of enabling diagnosis followed by therapy in the same patient with the same radiopharmaceutical. This would be an exciting development with a very promising future, would be of invaluable benefit to patients with cancer, cardiovascular disease, and other disorders, and may very well mark the future of the field of nuclear medicine.
